3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
48
Nivolumab
22
Cyclophosphamide
10
Carboplatin
10
spartalizumab
8
atezolizumab
7
Gemcitabine
7
130-nm albumin-bound paclitaxel
7
fludarabine
6
Cisplatin
6
Ipilimumab
5
durvalumab
4
budigalimab
4
avelumab
4
Pemetrexed
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Irinotecan
4
Interleukin-2
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
Bevacizumab
4
cemiplimab
3
cabozantinib
3
aldesleukin
3
Standard of Care
3
Specimen Handling
3
Oxaliplatin
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
utomilumab
×
Thoracic
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts